5 Key Takeaways

• 1

  The phase 3 REVEAL-1 trial enrolled 132 adults with moderate-to-severe active thyroid eye disease and randomized them to subcutaneous elegrobart every 4 weeks, every 8 weeks, or placebo.

• 2

  At week 24, proptosis response rates were 54% with every-4-week elegrobart and 63% with every-8-week dosing, versus 18% with placebo.

• 3

  Mean proptosis reductions at week 24 were 2.33 mm and 2.50 mm with every-4-week and every-8-week elegrobart, respectively, versus 0.81 mm with placebo.

• 4

  Among patients with baseline diplopia, response and complete resolution rates were 71% and 51% with every-4-week elegrobart, versus 32% and 16% with placebo.

• 5

  Most adverse events were mild; muscle spasms occurred in 41% and 36% of patients receiving every-4-week and every-8-week elegrobart, respectively, versus 7% with placebo.